<DOC>
	<DOCNO>NCT01750853</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability LY3045697 single dose , determine long LY3045697 remain body . Two cohort ( group ) 9 participant participate 3 dose period . These participant receive placebo one period . A third cohort 9 participate 2 dose period participant receive either 2 dose level LY3045697 1 dose level LY3045697 placebo end period .</brief_summary>
	<brief_title>A Study LY3045697 Healthy Participants</brief_title>
	<detailed_description>Cohort 3 add per protocol amendment ( April , 2013 ) .</detailed_description>
	<criteria>Are healthy male female nonchild bear potential determined medical history physical examination Male participant must agree use medically accept method contraception sexual partner study 90 day end final dosing Female participant must postmenopausal surgically sterile Postmenopausal female participant age 45 65 year , inclusive must 12 month without menstrual period 612 month without menstrual period FollicleStimulating Hormone ( FSH ) great ( &gt; ) 40 International Units per Liter ( IU/L ) Have body mass index ( BMI ) 18.0 32.5 kilogram per square meter ( kg/m² ) , inclusive , entry Have clinical laboratory test result within normal reference range population investigator site result acceptable deviation judge clinically significant Medical Investigator ( MI ) Have venous access sufficient allow blood sampling Are nonsmokers smoker 5 less cigarettes/cigars/pipes per day determine history Have ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` power drink '' ) , poppy seed , tobacco product 48 hour prior entry clinical research center discharge Are currently enrol , discontinue within last 60 day prior drug administration inclusive clinical trial involve investigational drug receive regulatory approval indication Have previously complete withdrawn study study investigate study drug Have history presence medical illness include limited cardiovascular , hepatic , respiratory , hematological , endocrine , psychiatric neurological disease , clinically significant laboratory abnormality , judgment MI , indicate medical problem would preclude study participation Have abnormality 12lead electrocardiogram ( ECG ) , opinion MI , increase risk associate participate study . In addition , participant follow finding exclude : Confirmed correct QT ( QTcF ) interval &gt; 450 millisecond ( msec ) males &gt; 470 msec female ; additional ECGs may perform required Complete bundle branch block conduction abnormality mild first degree atrioventricular block Irregular rhythm sinus arrhythmia occasional , rare supraventricular ectopic beat History unexplained syncope Family history unexplained sudden death sudden death due long QT syndrome Twave configuration sufficient quality assess QT interval , determine MI Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody , hepatitis C and/or positive hepatitis C antibody , hepatitis B and/or positive hepatitis B surface antigen ( HBsAg ) Intend use overthecounter prescription medication within 5 day prior dose , daily multivitamin therapy , stable thyroid hormone replacement medication assess acceptable MI interfere integrity study data collection . Medications benign indication healthy participant may continue , exception drug may alter adrenal function , blood pressure potassium Have donate blood 50 milliliter ( mL ) blood within 60 day prior dose Have average weekly alcohol intake exceed 21 unit per week participant unwilling stop alcohol within 48 hour entry study discharge period ( 1 unit = 12 ounce ( oz ) 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Have abnormal blood pressure ( supine ) define diastolic blood pressure &gt; 95 less ( &lt; ) 50 millimeter mercury ( mmHg ) and/or systolic blood pressure &gt; 150 &lt; 90 mmHg confirm least 1 repeat measurement Regularly use know drug abuse show positive finding use urinary drug screening Use natural licorice ( glycyrrhizinic acid ) within 5 day enrollment use study Are unwilling abstain use grapefruitcontaining product saltsubstitutes contain potassium duration study Have serum potassium &gt; upper limit normal ( result suspect hemolyzed sample may repeat ) &lt; low limit normal per lab reference range Have serum creatinine &gt; 124 micromoles per liter ( μmol/L ) ( male ) ; &gt; 106 μmol/L ( female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>